Chronic hepatitis C
Conditions
Interventions
Treat with Elbasvir/Grazoprevir combination therapy ERELSA 50mg:one tablet once a day for 12 weeks GRAZYNA 50mg:two tablets once a day for 12 weeks
Sponsors
Nippon Medical School Chiba Hokusoh Hospital
Nippon Medical School Hospital Nippon Medical School Musashi Kosugi Hospital The Jikei University Hospital Otakanomori Hospital Hakujikai Healthcare foundation Tokyo Metropolitan Bokutoh Hospital Tokyo Medical University Ibaraki Medical Center Shinmatsudo Central General Hospital Japanese Red Cross Narita Hospital Nagoya City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who treated with Elbasvir/Grazoprevir combination therapy. Patients with chronic hepatits C, genotype 1
Exclusion criteria
Exclusion criteria: 1.History of allergy to Elbasvir/Grazoprevir 2.Decompensated liver cirrhosis 3.pregnant woman or lactating mother 4.Hepatocellular carcinoma, or other malignant tumor. 5.severe depression 6.Judged by investigator not to be appropriate for inclusion in this study 7.Receiving contraindicated drugs for Elbasvir/Grazoprevir combined therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained virological response 12 rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in serum HCV RNA during treatment and follow-up duration 2. Change in hematological and biochemical test during treatment and follow-up duration 3. Change in Mac-2 Binding Protein,hyaluronic acid, type IV collagen,gamma globulin during treatment and follow-up duration. | — |
Countries
Japan
Contacts
Public ContactTomomi Okubo
Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology
Outcome results
None listed